The Future of Alzheimer's Diagnosis: How Blood-Based Biomarkers Are Changing Care

The future of Alzheimer's diagnosis is here—and it's happening with a simple blood test.In this episode, we explore how blood-based biomarkers are transforming the detection and management of Alzheimer's disease. Learn how innovative tests measuring biomarkers like P-TAU217 are providing highly accurate, less invasive alternatives to traditional PET scans and cerebrospinal fluid testing, making earlier diagnosis more accessible than ever.We also discuss the critical role clinical laboratories play in implementing these advanced diagnostic technologies, the infrastructure required to support high-sensitivity testing, and how labs are helping monitor the effectiveness and safety of emerging Alzheimer's therapies. As personalized medicine continues to evolve, laboratory diagnostics are becoming an essential part of improving patient outcomes and supporting long-term disease management.In this episode, you'll learn:How blood-based biomarkers are changing Alzheimer's diagnosisWhy P-TAU217 is emerging as a key diagnostic markerThe shift from imaging to serum-based testingLaboratory challenges and opportunities in high-sensitivity diagnosticsHow blood tests are supporting personalized treatment monitoring for Alzheimer's patientsWhether you're a laboratory professional, healthcare leader, or simply interested in the latest advancements in diagnostic medicine, this episode offers valuable insights into one of the fastest-growing areas of laboratory innovation.